2024 annual financial data
Evommune 2024 Operating cash flow margin
Direct answer
Operating cash flow margin was -831.36%.
Operating income was -70,013,000 USD and net income was -66,808,000 USD.
Operating cash flow was -58,195,000 USD.
Get free Evommune email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 7,000,000 USD
- Operating income
- -70,013,000 USD
- Net income
- -66,808,000 USD
- Operating cash flow
- -58,195,000 USD